Sharing this page with your friends could help raise up to 3x more in donations
Oxycodone 30mg cannot be bought online through professional home service paths as a Schedule II controlled substance reserved for opioid-tolerant patients with severe chronic pain unresponsive to lower-strength alternatives, requiring a valid EPCS prescription from a DEA-registered US provider; unauthorized online procurement constitutes federal felony distribution under 21 U.S.C. § 841(a)(1) with mandatory minimum 5-40 year imprisonment penalties plus asset forfeiture.
Roxicodone 30mg immediate-release (opioid-tolerant only, single dose >40mg respiratory arrest risk) titrates at 10-20% prior MME under 2025 CDC guidelines limiting acute scripts ≤3-7 days in 48 states, mandating synchronous HIPAA video NRS ≥8/10 + clean multi-state PDMP—no home service path circumvents post-12/31/2025 in-person exam, EPCS no-refill 7-day caps (#42 tabs maximum).
Oxycodone HCl 30mg IR (AUC 2100 ng*h/mL, Tmax 1.5h, t½ 3.5h CYP3A4/2D6), black box respiratory depression OR15 with naloxone co-prescription mandate >50 MME, overdose RR<8 SpO2<88%—taper 10-25% weekly Clinical Opiate Withdrawal Scale; contraindications paralytic ileus, acute asthma, MAOI 14 days.
Diagnostic: NRS ≥8/10 breakthrough + PEG ≤3 functional impairment 3+ months.
Video: PDMP zero fills 12mo, ORT <8, urine negative, QTc <500ms.
Mitigation: Naloxone 4mg nasal household standby.
EPCS: #42 tabs 30mg zero refills ≤7 days signature delivery.
Follow-up: ≥30% NRS q7d + random UDS/pill counts.
| Incidence Prevalence | Primary Cluster | Escalation Factors | Reversal Protocol |
|---|---|---|---|
| 45-65% | Constipation >3d, nausea | >60 MME initiation | Methylnaltrexone 12mg SC docusate TID ondansetron |
| 25-45% | Sedation RASS ≥-2, RR 8-12/min | CYP3A4i elderly | Naloxone 0.4mg IV q2min caffeine |
| 15-30% | Pruritus >20% BSA, hyperalgesia | >120 MME >90d | Tapentadol rotation gabapentin 300mg TID |
| 10-20% | Delirium CAM+>2, hypogonadism | >150 MME testosterone <300ng/dL | Haloperidol 0.5mg q6h labs q12w |
| 2-7% | Apnea RR<6 SpO2<85% | >200 MME pediatric | Naloxone 2mg IN x3 intubation GCS<8 |
Interactions: CYP3A4i (ketoconazole x4 AUC), benzodiazepines OR15 arrest, alcohol GABA.
| Strength | Max Tablets/Capsules | Days Supply | States Enforcing |
|---|---|---|---|
| Oxycodone 30mg IR | 180 tabs | 30 days | 42 states |
| >90 MME | Specialist required | All fills | 37 states |
| Acute initial | ≤7 days | 48 states | Universal PDMP check |
| MME Range | Hospitalization OR | Diversion Rate | Mandates |
|---|---|---|---|
| 1-49 | 1.0 | 5% | Baseline PDMP/naloxone |
| 50-89 | 2.2 | 18% | q14d UDS |
| 90-149 | 3.5 | 30% | Specialist consult |
| ≥150 | 8.9 | 45% | Rotation/taper |
Professional home service path legal absent EPCS? Negative—Ryan Haight felony 5-40 years.
Acute max supply 30mg strength? ≤7 days #42 tabs.
Opioid-tolerant single dose threshold? >40mg fatal risk.
Naloxone co-prescription trigger? >50 MME mandatory.